
Wockhardt pins future on novel antibiotics
The company is working on new antibiotics and has identified segments for a push into biosimilar drugs, chairman Habil Khorakiwala said, in the wake of promising results shown by Zaynich, an antibiotic it developed in-house. Wockhardt is in the process of …